Opko Health(OPK)

• Broad portfolio exposure across 50+ active trials spanning Phase 1–3, offering exposure to diverse therapeutic modalities (growth hormone, diabetes, oncology, rare disease, ophthalmology)
• Profitable diagnostics segment (4Kscore prostate cancer test) provides stable revenue foundation and clinical validation credibility
• Public company with $427M cash position (FY2025) enabling continued R&D investment and pipeline advancement

Generated by Claude from Opko Health's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Approved product with Phase 4 data generation ongoing; mature asset with limited growth trajectory.

Showing 5 of 10 publications